Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients

Alejo Erice; Sunwen Chou; Karen K. Biron; Sylvia C. Stanat; Henry H. Balfour; M. Colin Jordan

doi:10.1056/NEJM198902023200505

Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients

Alejo Erice, Sunwen Chou, Karen K. Biron, Sylvia C. Stanat, Henry H. Balfour, M. Colin Jordan

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

364 Scopus citations

Abstract

CYTOMEGALOVIRUS (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of bone marrow and solid-organ transplants and those with the acquired immunodeficiency syndrome (AIDS).¹ ² ³ ⁴ More than 90 percent of patients with AIDS are infected with CMV,⁴ and there is evidence of disseminated CMV at autopsy in 93 percent of this patient population.⁵ Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine) has been studied in preliminary clinical trials for the treatment of severe CMV disease in immunocompromised patients.⁶ ⁷ ⁸ ⁹ ¹⁰ ¹¹ ¹² ¹³ ¹⁴ ¹⁵ ¹⁶ ¹⁷ Although all studies have been uncontrolled, ganciclovir appears to be beneficial in CMV retinitis and in CMV involvement of the gastrointestinal….

Original language	English (US)
Pages (from-to)	289-293
Number of pages	5
Journal	New England Journal of Medicine
Volume	320
Issue number	5
DOIs	https://doi.org/10.1056/NEJM198902023200505
State	Published - Feb 2 1989

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1056/NEJM198902023200505

Find It

Find It at U of M Libraries

Cite this

@article{7cc9957d63584cd18701324a374fb43e,

title = "Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients",

abstract = "CYTOMEGALOVIRUS (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of bone marrow and solid-organ transplants and those with the acquired immunodeficiency syndrome (AIDS).1 2 3 4 More than 90 percent of patients with AIDS are infected with CMV,4 and there is evidence of disseminated CMV at autopsy in 93 percent of this patient population.5 Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine) has been studied in preliminary clinical trials for the treatment of severe CMV disease in immunocompromised patients.6 7 8 9 10 11 12 13 14 15 16 17 Although all studies have been uncontrolled, ganciclovir appears to be beneficial in CMV retinitis and in CMV involvement of the gastrointestinal….",

author = "Alejo Erice and Sunwen Chou and Biron, {Karen K.} and Stanat, {Sylvia C.} and Balfour, {Henry H.} and Jordan, {M. Colin}",

year = "1989",

month = feb,

day = "2",

doi = "10.1056/NEJM198902023200505",

language = "English (US)",

volume = "320",

pages = "289--293",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "5",

}

TY - JOUR

T1 - Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients

AU - Erice, Alejo

AU - Chou, Sunwen

AU - Biron, Karen K.

AU - Stanat, Sylvia C.

AU - Balfour, Henry H.

AU - Jordan, M. Colin

PY - 1989/2/2

Y1 - 1989/2/2

N2 - CYTOMEGALOVIRUS (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of bone marrow and solid-organ transplants and those with the acquired immunodeficiency syndrome (AIDS).1 2 3 4 More than 90 percent of patients with AIDS are infected with CMV,4 and there is evidence of disseminated CMV at autopsy in 93 percent of this patient population.5 Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine) has been studied in preliminary clinical trials for the treatment of severe CMV disease in immunocompromised patients.6 7 8 9 10 11 12 13 14 15 16 17 Although all studies have been uncontrolled, ganciclovir appears to be beneficial in CMV retinitis and in CMV involvement of the gastrointestinal….

AB - CYTOMEGALOVIRUS (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of bone marrow and solid-organ transplants and those with the acquired immunodeficiency syndrome (AIDS).1 2 3 4 More than 90 percent of patients with AIDS are infected with CMV,4 and there is evidence of disseminated CMV at autopsy in 93 percent of this patient population.5 Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine) has been studied in preliminary clinical trials for the treatment of severe CMV disease in immunocompromised patients.6 7 8 9 10 11 12 13 14 15 16 17 Although all studies have been uncontrolled, ganciclovir appears to be beneficial in CMV retinitis and in CMV involvement of the gastrointestinal….

UR - http://www.scopus.com/inward/record.url?scp=0024574822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024574822&partnerID=8YFLogxK

U2 - 10.1056/NEJM198902023200505

DO - 10.1056/NEJM198902023200505

M3 - Article

C2 - 2536135

AN - SCOPUS:0024574822

SN - 0028-4793

VL - 320

SP - 289

EP - 293

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -

Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this